Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases
- 857 Downloads
Bisphosphonates (BPs) are bone-remodeling inhibitors that are used to manage bone metastases and osteoporosis. Osteonecrosis of the jaw, however, can occur during treatment. This complication is poorly understood and is called “bisphosphonate-induced osteonecrosis of the jaw” (BIOJ).
We performed a PubMed-based review of all of the described cases of BIOJ from January 2003 (the year of the first description) to September 2009. Issues of clinical relevance, such as the primary diagnosis and type of treatment, were evaluated for each patient case.
We retrieved 2,408 cases, 88% of which were associated with intravenous therapy, primarily with zoledronate. Of the total number of cases, 89% were associated with the treatment of a malignant condition, particularly multiple myeloma (43% of the cases). Of all the BIOJ cases, 67% were preceded by tooth extraction and only 35% of patients were cured.
Prevention is better than treatment, and the establishment of meticulous oral hygiene and surgical procedures prior to commencing BP treatment is important for preventing BIOJ. Our review summarizes the current knowledge about this severe complication. Future studies, especially basic research studies, are needed to better understand this devastating disease.
KeywordsBisphosphonates Osteonecrosis of the jaws Epidemiology Retrospective
Conflict of interest statement
All authors disclose no financial and personal relationships with other people or organizations that could inappropriately influence (bias) the work. Olivier Filleul, Emerence Crompot, Sven Saussez.
- American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws (2007) J Oral Maxillofac Surg 65:369–376Google Scholar
- Curi MM, Cossolin GSI, Koga DH, Araùjo SR, Feher O, dos Santos MO et al (2007) Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: report of 3 cases. J Oral Maxillofac Surg 65:349–355CrossRefPubMedGoogle Scholar